MedTrace Logo

Study of 68Ga-R10602

NCT06745804 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-03-13

No results posted yet for this study

Summary

A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.

Conditions

  • Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
  • Metastatic Hormone Receptor Positive Breast Cancer
  • Hormone Receptor Positive Breast Adenocarcinoma

Interventions

DRUG

68Ga-R10602 injection

68Ga-R10602 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions in hormone receptor positive breast cancer

Sponsors & Collaborators

  • Radionetics Oncology

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-10
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06745804 on ClinicalTrials.gov